Biogen's Tau-Targeting Drug Slows Cognitive Decline in Alzheimer's Patients
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Biogen's leading tau-targeting candidate has slowed cognitive decline across a suite of different clinical assessments, backing up the pharma’s decision to race the molecule into phase 3 development.
The study provides the clearest evidence yet that medi
Biogen
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“The study provides the clearest evidence yet that medi”
biopharma dive — Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs“Biogen's leading tau-targeting candidate has slowed cognitive decline across a suite of different clinical assessments, backing up the pharma’s decision to race the molecule into phase 3 development.”
fierce biotech — <a href="/biotech/aaic-biogen-bolsters-hopes-pivotal-push-anti-tau-oligo-slows-cognitive-decline" hreflang="en">AAIC: Biogen bolsters hopes for Alzheimer's pivotal push as anti-tau oligo slows cognitive decline</a>“The year of daraxonrasib, a wearable for a myeloma drug, and more biotech news from The Readout”
stat news — STAT+: All eyes on data on Biogen’s tau therapy